VistaGen Therapeutics (VTGN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

VistaGen Therapeutics Revenue Highlights

Latest Revenue (Y)

$1.06M

Latest Revenue (Q)

$244.00K

Main Segment (Y)

License

Main Geography (Y)

License

VistaGen Therapeutics Revenue by Period

VistaGen Therapeutics Revenue by Year

Date	Revenue	Change
2024-03-31	$1.06M	-568.72%
2023-03-31	$-227.00K	-120.47%
2022-03-31	$1.11M	1.78%
2021-03-31	$1.09M	100.00%
2020-03-31	-	100.00%
2019-03-31	-	100.00%
2018-03-31	-	-100.00%
2017-03-31	$1.25M	100.00%
2016-03-31	-	100.00%
2015-03-31	-	100.00%
2014-03-31	-	-100.00%
2013-03-31	$200.40K	-85.07%
2012-03-31	$1.34M	100.00%
2010-12-31	-	100.00%
2009-12-31	-	100.00%
2008-12-31	-	100.00%
2007-12-31	-	-

VistaGen Therapeutics generated $1.06M in revenue during NA 2024, up -568.72% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

VistaGen Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-06-30	$244.00K	-1726.67%
2025-03-31	$-15.00K	-106.41%
2024-12-31	$234.00K	27.87%
2024-09-30	$183.00K	117.86%
2024-06-30	$84.00K	-57.43%
2024-03-31	$197.30K	-52.04%
2023-12-31	$411.40K	47.99%
2023-09-30	$278.00K	57.06%
2023-06-30	$177.00K	0.80%
2023-03-31	$175.60K	-2.23%
2022-12-31	$179.60K	-120.12%
2022-09-30	$-892.50K	-387.81%
2022-06-30	$310.10K	697.17%
2022-03-31	$38.90K	-89.13%
2021-12-31	$357.90K	-0.03%
2021-09-30	$358.00K	1.10%
2021-06-30	$354.10K	-19.87%
2021-03-31	$441.90K	40.91%
2020-12-31	$313.60K	-6.11%
2020-09-30	$334.00K	100.00%
2020-06-30	-	100.00%
2020-03-31	-	100.00%
2019-12-31	-	100.00%
2019-09-30	-	100.00%
2019-06-30	-	100.00%
2019-03-31	-	100.00%
2018-12-31	-	100.00%
2018-09-30	-	100.00%
2018-06-30	-	100.00%
2018-03-31	-	100.00%
2017-12-31	-	100.00%
2017-09-30	-	100.00%
2017-06-30	-	-100.00%
2017-03-31	$1.25B	99800.00%
2016-12-31	$1.25M	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	-100.00%
2012-06-30	$200.40K	-57.26%
2012-03-31	$468.93K	19727.95%
2011-12-31	$2.37K	-99.25%
2011-09-30	$316.29K	-42.97%
2011-06-30	$554.62K	100.00%
2011-03-31	-	100.00%
2010-12-31	-	100.00%
2010-09-30	-	100.00%
2010-06-30	-	100.00%
2010-03-31	-	100.00%
2009-12-31	-	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	-

VistaGen Therapeutics generated $244.00K in revenue during Q1 2026, up -1726.67% compared to the previous quarter, and up 123.67% compared to the same period a year ago.

VistaGen Therapeutics Revenue Breakdown

VistaGen Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Mar 22
License	$1.11M

VistaGen Therapeutics's latest annual revenue breakdown by segment (product or service), as of Mar 22: License (100.00%).

Quarterly Revenue by Product

Product/Service	Jun 23	Mar 22
License	$177.60K	$39.00K

VistaGen Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License (100.00%).

VistaGen Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Mar 22
License	$1.11M

VistaGen Therapeutics's latest annual revenue breakdown by geography, as of Mar 22: License (100.00%).

Quarterly Revenue by Country

Country	Mar 22
License	$39.00K

VistaGen Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: License (100.00%).

VistaGen Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AGEN	Agenus	$103.46M	$30.23M
SPRO	Spero Therapeutics	$47.98M	$11.80M
SEER	Seer	$14.17M	$4.12M
IRD	Opus Genetics	$10.99M	-
VTGN	VistaGen Therapeutics	$1.06M	$244.00K
ACTU	Actuate Therapeutics	-	-
MCRB	Seres Therapeutics	-	$351.00K
INO	Inovio Pharmaceuticals	-	-
CGTX	Cognition Therapeutics	-	-
ABOS	Acumen Pharmaceuticals	-	-
HURA	TuHURA Biosciences	-	-

VTGN Revenue FAQ

What is VistaGen Therapeutics’s yearly revenue?

VistaGen Therapeutics's yearly revenue for 2024 was $1.06M, representing a decrease of -568.72% compared to 2023. The company's yearly revenue for 2023 was $-227K, representing a decrease of -120.47% compared to 2022. VTGN's yearly revenue for 2022 was $1.11M, representing an increase of 1.78% compared to 2021.

What is VistaGen Therapeutics’s quarterly revenue?

VistaGen Therapeutics's quarterly revenue for Q1 2026 was $244K, a -1726.67% decrease from the previous quarter (Q4 2025), and a 190.48% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $-15K, a -106.41% decrease from the previous quarter (Q3 2025), and a -107.60% decrease year-over-year (Q4 2024). VTGN's quarterly revenue for Q3 2025 was $234K, a 27.87% increase from the previous quarter (Q2 2025), and a -43.12% decrease year-over-year (Q3 2024).

What is VistaGen Therapeutics’s revenue growth rate?

VistaGen Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -4.05%, and for the last 5 years (2020-2024) was 0%.

What are VistaGen Therapeutics’s revenue streams?

VistaGen Therapeutics's revenue streams in r 22 are License

What is VistaGen Therapeutics’s main source of revenue?

For the fiscal year ending Mar 22, the largest source of revenue of VistaGen Therapeutics was License. This segment made a revenue of $1.11M, representing 100.00% of the company's total revenue.